In the present study we provide several lines of evidence that the antiproliferative effect of zoledronic acid depends on the KRAS-status of human NSCLC-lines, mutant KRAS showed resistance, while wild type KRAS could be inhibited in vitro as well as in vivo affecting proliferation and growth of the tumor. Here, KRAS is linked to neoplasm.